Cargando…

Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer

BACKGROUND: Increasing evidence indicates that loss of muscle mass is associated with adverse outcomes in metastatic colorectal cancer. Here, we investigate which demographic, lifestyle- (smoking), tumor-, and treatment-related factors are associated with muscle loss in patients with metastatic colo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derksen, Jeroen W G, Kurk, Sophie A, Oskam, Marieke J, Peeters, Petra H M, Punt, Cornelis J A, Koopman, Miriam, May, Anne M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649832/ https://www.ncbi.nlm.nih.gov/pubmed/31360897 http://dx.doi.org/10.1093/jncics/pkz016

Ejemplares similares

Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients
por: Kurk, Sophie A, et al.
Publicado: (2019)

The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer
por: Derksen, Jeroen W.G., et al.
Publicado: (2020)

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients
por: Kurk, Sophie A., et al.
Publicado: (2018)

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
por: Kurk, Sophie, et al.
Publicado: (2019)

Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial
por: Kurk, Sophie A., et al.
Publicado: (2019)

Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data
por: Hamers, Patricia A. H., et al.
Publicado: (2020)

Feasibility of 7-T fluorine magnetic resonance spectroscopic imaging ((19)F MRSI) for TAS-102 metabolite detection in the liver of patients with metastatic colorectal cancer
por: Kurk, Sophie A., et al.
Publicado: (2018)

EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer
por: Venderbosch, Sabine, et al.
Publicado: (2015)

MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer
por: Simmer, Femke, et al.
Publicado: (2015)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Inventory of oncologists’ unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer
por: Engelhardt, Ellen G., et al.
Publicado: (2018)

Time‐varying prognostic value of primary tumor sidedness in metastatic colorectal cancer: A population‐based study and meta‐analysis
por: van der Kruijssen, Dave E. W., et al.
Publicado: (2022)

Genomic landscape of metastatic colorectal cancer
por: Haan, Josien C., et al.
Publicado: (2014)

Mitochondrial microsatellite instability in patients with metastatic colorectal cancer
por: Venderbosch, S., et al.
Publicado: (2015)

Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
por: Franken, Mira D., et al.
Publicado: (2020)

Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials
por: Goey, Kaitlyn K H, et al.
Publicado: (2017)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
por: ’t Lam - Boer, Jorine, et al.
Publicado: (2014)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
por: Pander, Jan, et al.
Publicado: (2015)

Management of cytotoxic chemotherapy-induced hand-foot syndrome
por: Kwakman, Johannes J.M., et al.
Publicado: (2020)

Translation of IDEA trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer
por: van Rooijen, Karlijn L., et al.
Publicado: (2022)

Limited effect of lymph node status on the metastatic pattern in colorectal cancer
por: Knijn, Nikki, et al.
Publicado: (2016)

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
por: McCleary, Nadine J, et al.
Publicado: (2022)

ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer
por: Trumpi, K., et al.
Publicado: (2015)

Colorectal Cancer Care and Patients’ Perceptions Before and During COVID-19: Implications for Subsequent SARS-CoV-2 Infection Waves
por: Derksen, Jeroen W G, et al.
Publicado: (2021)

The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care
por: Derksen, Jeroen W. G., et al.
Publicado: (2021)

Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data
por: Trinh, Anne, et al.
Publicado: (2018)

A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
por: Hamblin, T. J., et al.
Publicado: (1993)

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
por: Bennett, L, et al.
Publicado: (2011)

Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer
por: Bosch, Linda J.W., et al.
Publicado: (2017)

Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Prognostic value of Lynch syndrome, BRAF(V600E) , and RAS mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023)

Model-based evaluation of the cost effectiveness of 3 versus 6 months’ adjuvant chemotherapy in high-risk stage II colon cancer patients
por: Jongeneel, Gabrielle, et al.
Publicado: (2020)

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival
por: Brouwer, Nelleke P. M., et al.
Publicado: (2019)

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
por: Smeets, Dominiek, et al.
Publicado: (2018)

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019)

Optimizing the first-line treatment for metastatic colorectal cancer
por: Cherri, Sara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3hlj8p6rlutqmhiob3kmifrmhu